• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B 细胞限制性分子 CD22 的表达与功能

Expression and function of CD22, a B-cell restricted molecule.

作者信息

Moyron-Quiroz J E, Partida-Sánchez S, Donís-Hernández R, Sandoval-Montes C, Santos-Argumedo L

机构信息

Department of Cellular Biology, Centro de Investigación y Estudios Avanzados del I.P.N., 07360 México D.F., México.

出版信息

Scand J Immunol. 2002 Apr;55(4):343-51. doi: 10.1046/j.1365-3083.2002.01063.x.

DOI:10.1046/j.1365-3083.2002.01063.x
PMID:11967115
Abstract

In this work, we studied the expression and function of CD22 in murine B cells. CD22 has been previously characterized as an activation marker of mature B lymphocytes. However, we found that CD22 is expressed early during the ontogeny of B cells in the bone marrow and spleen, and was found on B cells isolated from all the different lymphoid compartments. We also found that B cells stimulated through the B-cell antigen receptor (BCR), CD38 and CD40, upregulated CD22 expression to maximal levels within 24 h after stimulation, but that the levels of CD22 declined at later times (48 and 72 h). CD22 is rapidly phosphorylated after BCR signal transduction, and is believed to downregulate B-cell activation. In this study, we did not detect CD22 phosphorylation in activated B cells after CD38 or CD40 cross-linking, even though CD22 was clearly phosphorylated in the BCR-stimulated B cells. Consistent with this, we found no evidence of physical association between CD38 or CD40 and CD22 in B cells. The lack of association or phosphorylation of CD22 induced by CD38 and CD40 cross-linking indicates that CD22 may not downregulate the activation induced by these two molecules.

摘要

在本研究中,我们研究了CD22在小鼠B细胞中的表达及功能。CD22先前已被表征为成熟B淋巴细胞的活化标志物。然而,我们发现CD22在骨髓和脾脏中B细胞的个体发育早期即有表达,并且在从所有不同淋巴区室分离出的B细胞上均能检测到。我们还发现,通过B细胞抗原受体(BCR)、CD38和CD40刺激的B细胞,在刺激后24小时内将CD22表达上调至最高水平,但CD22的水平在随后的时间(48和72小时)下降。BCR信号转导后CD22迅速磷酸化,并且被认为可下调B细胞活化。在本研究中,我们未检测到CD38或CD40交联后活化B细胞中的CD22磷酸化,尽管在BCR刺激的B细胞中CD22明显发生了磷酸化。与此一致,我们未发现B细胞中CD38或CD40与CD22之间存在物理关联的证据。CD38和CD40交联诱导的CD22缺乏关联或磷酸化表明,CD22可能不会下调由这两种分子诱导的活化。

相似文献

1
Expression and function of CD22, a B-cell restricted molecule.B 细胞限制性分子 CD22 的表达与功能
Scand J Immunol. 2002 Apr;55(4):343-51. doi: 10.1046/j.1365-3083.2002.01063.x.
2
Inhibitory coreceptors activated by antigens but not by anti-Ig heavy chain antibodies install requirement of costimulation through CD40 for survival and proliferation of B cells.由抗原而非抗Ig重链抗体激活的抑制性共受体通过CD40安装了B细胞存活和增殖的共刺激需求。
J Immunol. 2003 Aug 15;171(4):1835-43. doi: 10.4049/jimmunol.171.4.1835.
3
Regulation of MHC class II signal transduction by the B cell coreceptors CD19 and CD22.B细胞共受体CD19和CD22对MHC II类信号转导的调控。
J Immunol. 2000 Nov 15;165(10):5588-96. doi: 10.4049/jimmunol.165.10.5588.
4
CD22 is a negative regulator of B-cell receptor signalling.CD22是B细胞受体信号传导的负调节因子。
Curr Biol. 1997 Feb 1;7(2):133-43. doi: 10.1016/s0960-9822(06)00057-1.
5
B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling.在缺乏SLP65/BLNK的小鼠中,B细胞缺陷可因缺乏CD22(一种BCR信号传导的抑制性共受体)而得到部分纠正。
Eur J Immunol. 2003 Dec;33(12):3418-26. doi: 10.1002/eji.200324290.
6
Ontogeny, distribution and function of CD38-expressing B lymphocytes in mice.小鼠中表达CD38的B淋巴细胞的个体发生、分布及功能
Eur J Immunol. 2001 Apr;31(4):1261-7. doi: 10.1002/1521-4141(200104)31:4<1261::AID-IMMU1261gt;3.0.CO;2-H.
7
Differentially regulated expression and function of CD22 in activated B-1 and B-2 lymphocytes.活化的B-1和B-2淋巴细胞中CD22的差异调节表达及功能
J Immunol. 2002 Jun 15;168(12):6078-83. doi: 10.4049/jimmunol.168.12.6078.
8
Negative regulation of B cell receptor-mediated signaling in B-1 cells through CD5 and Ly49 co-receptors via Lyn kinase activity.通过Lyn激酶活性,经由CD5和Ly49共受体对B-1细胞中B细胞受体介导的信号传导进行负调控。
Int Immunol. 2000 Oct;12(10):1417-23. doi: 10.1093/intimm/12.10.1417.
9
Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.利用双特异性抗体通过CD22和CD38将核糖体失活蛋白格列诺素递送至淋巴瘤细胞。
Br J Cancer. 1995 May;71(5):986-94. doi: 10.1038/bjc.1995.190.
10
CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1.CD22通过两个分别招募Grb2和SHP-1的结构域调节B细胞受体介导的信号。
J Biol Chem. 2001 Nov 23;276(47):44315-22. doi: 10.1074/jbc.M105446200. Epub 2001 Sep 10.

引用本文的文献

1
An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia.使用负载CRISPR的功能化纳米载体在体内生成CAR-T细胞用于治疗B细胞系急性淋巴细胞白血病的综述。
Mol Biol Rep. 2025 Jun 14;52(1):596. doi: 10.1007/s11033-025-10674-1.
2
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.用于系统性红斑狼疮的嵌合抗原受体T细胞疗法:现状与未来展望
Front Immunol. 2024 Dec 19;15:1476859. doi: 10.3389/fimmu.2024.1476859. eCollection 2024.
3
Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.
mRNA 靶向递送至免疫细胞以增强癌症治疗的进展。
Theranostics. 2024 Sep 3;14(14):5528-5550. doi: 10.7150/thno.93745. eCollection 2024.
4
Single-cell transcriptome sequencing reveals altered peripheral blood immune cells in patients with severe tuberculosis.单细胞转录组测序揭示重症结核病患者外周血免疫细胞的改变。
Eur J Med Res. 2024 Aug 29;29(1):434. doi: 10.1186/s40001-024-01991-5.
5
From mechanism to therapy: the journey of CD24 in cancer.从机制到治疗:CD24 在癌症中的作用。
Front Immunol. 2024 May 31;15:1401528. doi: 10.3389/fimmu.2024.1401528. eCollection 2024.
6
CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation.CD22 与胰岛素缀合可减弱胰岛素特异性 B 细胞的活化。
Bioconjug Chem. 2023 Nov 15;34(11):2077-2088. doi: 10.1021/acs.bioconjchem.3c00391. Epub 2023 Oct 26.
7
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.利用新型高灵敏度 aCD22 CAR 对 B-ALL 进行 CD19 和 CD22 的双重靶向治疗。
Mol Ther. 2023 Jul 5;31(7):2089-2104. doi: 10.1016/j.ymthe.2023.03.020. Epub 2023 Mar 21.
8
Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential.CD22特异性嵌合抗原受体修饰的T细胞上程序性死亡配体1的表达会削弱抗肿瘤潜力。
MedComm (2020). 2022 May 29;3(2):e140. doi: 10.1002/mco2.140. eCollection 2022 Jun.
9
Immunological effects of cerebral palsy and rehabilitation exercises in children.儿童脑瘫及康复训练的免疫学效应
Brain Behav Immun Health. 2021 Oct 9;18:100365. doi: 10.1016/j.bbih.2021.100365. eCollection 2021 Dec.
10
Nanomedicines in B cell-targeting therapies.纳米药物在 B 细胞靶向治疗中的应用。
Acta Biomater. 2022 Jan 1;137:1-19. doi: 10.1016/j.actbio.2021.10.024. Epub 2021 Oct 21.